Claims
- 1. A method for producing a 34 kDa truncated plasmin proteolytic protein comprising combining plasminogen and rPAI-123 for a specified amount of time and adding uPA so that a 34 kDa truncated plasmin proteolytic protein is produced.
- 2. A 34 kDa truncated plasmin proteolytic protein produced by the method of claim 1.
- 3. A method for modulating the expression of a membrane type 1-matrix metalloproteinase comprising administering an effective amount of an plasminogen activator inhibitor type 1 isoform lacking a reactive center loop and containing a complete heparin-binding domain or lacking at least a portion of a heparin-binding domain so that the expression of a membrane type 1-matrix metalloproteinase is modulated.
- 4. The method of claim 3, wherein the plasminogen activator inhibitor type isoform contains the heparin-binding domain and increases expression of a membrane type 1-matrix metalloproteinase.
- 5. The method of claim 3, wherein the plasminogen activator inhibitor type isoform lacks a portion of the heparin-binding domain and decreases expression of a membrane type 1-matrix metalloproteinase.
INTRODUCTION
[0001] This application is a continuation-in-part of PCT/US03/09981, filed Apr. 1, 2003, and claims the benefit of priority from U.S. provisional application Serial No. 60/448,301, filed Feb. 14, 2003, and U.S. provisional application Serial No. 60/369,392, filed Apr. 1, 2002, whose contents are incorporated herein by reference in their entireties. This invention was supported in part by funds from the U.S. government (NIH NHLB1 Grant No. Rβ1-HL59590) and the U.S. government may therefore have certain rights in the invention.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60448301 |
Feb 2003 |
US |
|
60369392 |
Apr 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/US03/09981 |
Apr 2003 |
US |
Child |
10686428 |
Oct 2003 |
US |